Unique ID issued by UMIN | UMIN000001229 |
---|---|
Receipt number | R000001497 |
Scientific Title | Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy (PEACE) |
Date of disclosure of the study information | 2008/08/01 |
Last modified on | 2012/07/02 17:22:46 |
Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy (PEACE)
Pitavastatin on carotid intima-media thickness
Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-Lowering Therapy (PEACE)
Pitavastatin on carotid intima-media thickness
Japan |
hyperlipidemia
carotid artery atherosclerosis
Cardiology | Endocrinology and Metabolism |
Others
NO
This study is aimed to analyze the effects of aggressive and conventional lipid lowering therapy with Pitavastatin on carotid intima-media thickness (IMT) in patients with hyperlipidemia and abnormal thickening of IMT.
Safety,Efficacy
Confirmatory
Explanatory
Not applicable
absolute changes in carotid intima-media thickness from baseline to final visit (12 months)
relative change in carotid intima-media thickness
change in LDL-C, HDL-C, TG and RLP-C
change in hs-CRP and IL-6
new onset or recurrence of ischemic heart disease, heart failure, stroke and atherosclerosis obliterans
sudden death
side effects
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Subjects who are diagnosed as having hyperlipidemia, and LDL-C at the time of enrollment is no less than 100
Subjects whose common carotid IMT is 1.1 mm and over
Subjects who received or are planned to receive intervention on carotid arteries during the study period
Subjects with overt liver dysfunction (ALT; 100 IU/L and over)
Subjects with overt renal dysfunction (serum creatinine; 2.0 mg/dL and over)
Subjects receiving Cyclosporin
Subjects hyperreactive to Pitavastatin
Subjects with pregnancy or lactation
300
1st name | |
Middle name | |
Last name | Hiroaki Matsubara |
Kyoto Prefectural University of Medicine
Department of Cardiovascular Medicine
465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5511
1st name | |
Middle name | |
Last name |
Kyoto Prefectural University of Medicine
Department of Cardiovascular Medicine
465 Kajii-cho Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
075-251-5511
Department of Cardiovascular Medicine,
Kyoto Prefectural University of Medicine
Department of Cardiovascular Medicine,
Kyoto Prefectural University of Medicine
Self funding
YES
NCT00711919
ClinicalTrials.gov
2008 | Year | 08 | Month | 01 | Day |
Published
http://www.ncbi.nlm.nih.gov/pubmed/22689416
Completed
2007 | Year | 06 | Month | 08 | Day |
2007 | Year | 07 | Month | 01 | Day |
2009 | Year | 12 | Month | 01 | Day |
2008 | Year | 07 | Month | 02 | Day |
2012 | Year | 07 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001497